Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

390
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
390
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

873
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
873
Blood Typing01:10

Blood Typing

1.1K
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
1.1K
Rh Blood Group01:19

Rh Blood Group

1.4K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.4K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
The ABO Blood Group01:12

The ABO Blood Group

1.6K
The ABO blood group system is a critical element of transfusion medicine, essential for determining blood compatibility in transfusions and organ transplants. It is based on specific antigens, or agglutinogens, present on the surface of red blood cells (RBCs) and corresponding antibodies, or agglutinins, in the blood plasma.
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

HemaSphere·2026
Same author

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Annals of hematology·2026
Same author

Sutimlimab for cold agglutinin disease: an updated perspective from approval to real-world clinical treatment.

Expert review of hematology·2026
Same author

The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa).

American journal of hematology·2026
Same author

Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?

British journal of haematology·2026
Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026

Related Experiment Video

Updated: Jun 8, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.5K

Autoimmune haemolytic anaemias.

Marc Michel1, Etienne Crickx2, Bruno Fattizzo3,4

  • 1Department of Internal Medicine and Clinical Immunology, National Reference Centre for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France. marc.michel2@aphp.fr.

Nature Reviews. Disease Primers
|November 2, 2024
PubMed
Summary

Adult autoimmune haemolytic anaemias (AIHAs) are rare autoimmune disorders causing red blood cell destruction. Recent advancements like complement inhibitors offer new hope for treating these complex conditions.

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

761
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

134.5K

Related Experiment Videos

Last Updated: Jun 8, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.5K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

761
Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

134.5K

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Adult autoimmune haemolytic anaemias (AIHAs) involve autoantibodies destroying red blood cells (RBCs).
  • Diagnosis relies on the direct antiglobulin test, classifying AIHAs into warm, cold, or mixed types based on autoantibody characteristics.
  • Warm AIHAs (wAIHAs) involve IgG autoantibodies and occur with underlying conditions in about 50% of cases, while cold AIHAs are IgM antibody-driven.

Purpose of the Study:

  • To provide an overview of adult autoimmune haemolytic anaemias.
  • To discuss the classification, pathogenesis, and diagnostic approaches for AIHAs.
  • To highlight recent therapeutic advancements and future directions in AIHA management.

Main Methods:

  • Literature review of AIHA classification, diagnosis, and treatment.
  • Summary of current understanding of warm AIHAs (wAIHAs) and cold AIHAs, including cold agglutinin disease (CAD).
  • Discussion of established and emerging therapies, including corticosteroids, splenectomy, rituximab, and complement inhibitors.

Main Results:

  • AIHAs are classified into warm, cold, and mixed types based on autoantibody properties.
  • Warm AIHAs (wAIHAs) involve IgG autoantibodies and spleen-mediated RBC destruction.
  • Cold AIHAs are driven by IgM antibodies and complement activation, leading to haemolysis.

Conclusions:

  • Traditional treatments for wAIHAs include corticosteroids and splenectomy, while cold AIHAs rely on symptomatic measures and cytotoxic agents.
  • The therapeutic landscape for AIHAs is evolving with the introduction of targeted therapies like rituximab and complement inhibitors (e.g., sutimlimab).
  • Ongoing research into novel targeted therapies promises improved outcomes for patients with AIHAs.